Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Goldman Sachs Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
March 10, 2025 4:03 PM EDTGoldman Sachs analyst Richard Law reiterated a Buy rating and $24.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
The analyst comments "Earlier this morning, MLYS presented positive topline data for lorundrostat's pivotal Ph. 3 Launch-HTN and Ph. 2 Advance-HTN studies in 3/4L uncontrolled and resistant hypertension (uHTN/rHTN). Launch-HTN met its primary endpoint, with placebo-adjusted SBP reductions of 9.1 mmHg (16.9 mmHg absolute)... More
